About Acticor Biotech
Acticor Biotech is a company based in Paris (France) founded in 2013.. Acticor Biotech has raised $31.36 million across 7 funding rounds from investors including Bpifrance, GO CAPITAL and Anaxago. Acticor Biotech offers products and services including Glenzocimab. Acticor Biotech operates in a competitive market with competitors including Alexion, argenx, BigHat, Kodiak Sciences and Visterra, among others.
- Headquarter Paris, France
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Acticor Biotech Sa
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$31.36 M (USD)
in 7 rounds
-
Latest Funding Round
$7.77 M (USD), Series B
Nov 06, 2019
-
Investors
Bpifrance
& 6 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Acticor Biotech
Acticor Biotech offers a comprehensive portfolio of products and services, including Glenzocimab. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Drug for treating acute ischemic stroke and cardiovascular emergencies.
Unlock access to complete
Unlock access to complete
Funding Insights of Acticor Biotech
Acticor Biotech has successfully raised a total of $31.36M across 7 strategic funding rounds. The most recent funding activity was a Series B round of $7.77 million completed in November 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Series B — $7.8M
-
First Round
First Round
(26 Jan 2015)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2019 | Amount | Series B - Acticor Biotech | Valuation | GO CAPITAL | |
| Oct, 2018 | Amount | Series B - Acticor Biotech | Valuation | Newton Biocapital | |
| Jan, 2018 | Amount | Series B - Acticor Biotech | Valuation | Primer Capital |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Acticor Biotech
Acticor Biotech has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Bpifrance, GO CAPITAL and Anaxago. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investments are directed toward multiple sectors.
|
Founded Year | Domain | Location | |
|
Investments are focused on life sciences in Europe and Japan.
|
Founded Year | Domain | Location | |
|
Karista is recognized as an early-stage venture capital firm.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Acticor Biotech
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Acticor Biotech
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Acticor Biotech Comparisons
Competitors of Acticor Biotech
Acticor Biotech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alexion, argenx, BigHat, Kodiak Sciences and Visterra, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapies for rare and devastating diseases are developed by Alexion.
|
|
| domain | founded_year | HQ Location |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment.
|
|
| domain | founded_year | HQ Location |
Antibody therapies are developed through machine learning and synthetic biology.
|
|
| domain | founded_year | HQ Location |
Therapeutics for retinal diseases are developed by the company.
|
|
| domain | founded_year | HQ Location |
Developer of monoclonal antibodies against infectious diseases
|
|
| domain | founded_year | HQ Location |
Antibody-based drugs for primary myopathies are developed and targeted.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Acticor Biotech
Frequently Asked Questions about Acticor Biotech
When was Acticor Biotech founded?
Acticor Biotech was founded in 2013 and raised its 1st funding round 2 years after it was founded.
Where is Acticor Biotech located?
Acticor Biotech is headquartered in Paris, France.
Who is the current CEO of Acticor Biotech?
Gilles Avenard is the current CEO of Acticor Biotech.
Is Acticor Biotech a funded company?
Acticor Biotech is a funded company, having raised a total of $31.36M across 7 funding rounds to date. The company's 1st funding round was a Series B of $2.05M, raised on Jan 26, 2015.
What does Acticor Biotech do?
Acticor Biotech was founded in 2013 in Paris, France, within the biotechnology sector. Therapeutic monoclonal antibodies are developed by the company for ischemic stroke treatment. Focus is placed on ACT-017, a humanized antibody targeting platelet glycoprotein VI in cerebral stroke cases. Operations center on advancing these immunotherapeutics through research and development processes.
Who are the top competitors of Acticor Biotech?
Acticor Biotech's top competitors include argenx, Kodiak Sciences and MacroGenics.
What products or services does Acticor Biotech offer?
Acticor Biotech offers Glenzocimab.
Who are Acticor Biotech's investors?
Acticor Biotech has 7 investors. Key investors include Bpifrance, GO CAPITAL, Anaxago, Newton Biocapital, and Karista.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.